|
1
|
Núñez M: Hepatotoxicity of
antiretrovirals: Incidence, mechanisms and management. J Hepatol.
44(1 Suppl): S132–S139. 2006. View Article : Google Scholar
|
|
2
|
Sun L and Hui L: Progress in human liver
organoids. J Mol Cell Biol. 12:607–617. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xiao J, Wang F, Wong NK, He J, Zhang R,
Sun R, Xu Y, Liu Y, Li W, Koike K, et al: Global liver disease
burdens and research trends: Analysis from a Chinese perspective. J
Hepatol. 71:212–221. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Han H, Desert R, Das S, Song Z, Athavale
D, Ge X and Nieto N: Danger signals in liver injury and restoration
of homeostasis. J Hepatol. 73:933–951. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Terrault NA, Francoz C, Berenguer M,
Charlton M and Heimbach J: Liver transplantation 2023: Status
report, current and future challenges. Clin Gastroenterol Hepatol.
21:2150–2166. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wong MCS, Huang JLW, George J, Huang J,
Leung C, Eslam M, Chan HLY and Ng SC: The changing epidemiology of
liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol
Hepatol. 16:57–73. 2019. View Article : Google Scholar
|
|
7
|
Chen J, Ruan X, Fu T, Lu S, Gill D, He Z,
Burgess S, Giovannucci EL, Larsson SC, Deng M, et al: Sedentary
lifestyle, physical activity, and gastrointestinal diseases:
Evidence from mendelian randomization analysis. EBioMedicine.
103:1051102024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Devarbhavi H, Asrani SK, Arab JP, Nartey
YA, Pose E and Kamath PS: Global burden of liver disease: 2023
update. J Hepatol. 79:516–537. 2023. View Article : Google Scholar
|
|
9
|
Li JZ, Cai XB and Lu LG: Endoscopic
ultrasound-guided liver biopsy: Current status and prospects).
Zhonghua Gan Zang Bing Za Zhi. 32:572–576. 2024.In Chinese.
PubMed/NCBI
|
|
10
|
Li M, Luo Q, Tao Y, Sun X and Liu C:
Pharmacotherapies for drug-induced liver injury: A current
literature review. Front Pharmacol. 12:8062492021. View Article : Google Scholar
|
|
11
|
Pose E, Napoleone L, Amin A, Campion D,
Jimenez C, Piano S, Roux O, Uschner FE, de Wit K, Zaccherini G, et
al: Safety of two different doses of simvastatin plus rifaximin in
decompensated cirrhosis (LIVERHOPE-SAFETY): A randomised,
double-blind, placebo-controlled, phase 2 trial. Lancet
Gastroenterol Hepatol. 5:31–41. 2020. View Article : Google Scholar
|
|
12
|
Bataller R, Arab JP and Shah VH:
Alcohol-Associated hepatitis. N Engl J Med. 387:2436–2448. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang L, Deng Y, Bai X, Wei X, Ren Y, Chen
S and Deng H: Cell therapy for end-stage liver disease: Current
state and clinical challenge. Chin Med J (Engl). 137:2808–2820.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Artru F, Trovato F, Morrison M, Bernal W
and McPhail M: Liver transplantation for acute-on-chronic liver
failure. Lancet Gastroenterol Hepatol. 9:564–576. 2024. View Article : Google Scholar
|
|
15
|
Li Y, Ye Y and Chen H: Astragaloside IV
inhibits cell migration and viability of hepatocellular carcinoma
cells via suppressing long noncoding RNA ATB. Biomed Pharmacother.
99:134–141. 2018. View Article : Google Scholar
|
|
16
|
Yao L, Hu X, Dai K, Yuan M, Liu P, Zhang Q
and Jiang Y: Mesenchymal stromal cells: Promising treatment for
liver cirrhosis. Stem Cell Res Ther. 13:3082022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Volarevic V, Markovic BS, Gazdic M,
Volarevic A, Jovicic N, Arsenijevic N, Armstrong L, Djonov V, Lako
M and Stojkovic M: Ethical and safety issues of stem cell-based
therapy. Int J Med Sci. 15:36–45. 2018. View Article : Google Scholar :
|
|
18
|
Arab JP, Karpen SJ, Dawson PA, Arrese M
and Trauner M: Bile acids and nonalcoholic fatty liver disease:
Molecular insights and therapeutic perspectives. Hepatology.
65:350–362. 2017. View Article : Google Scholar :
|
|
19
|
Tilg H, Adolph TE, Dudek M and Knolle P:
Non-alcoholic fatty liver disease: The interplay between
metabolism, microbes and immunity. Nat Metab. 3:1596–1607. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ghazanfar H, Javed N, Qasim A, Zacharia
GS, Ghazanfar A, Jyala A, Shehi E and Patel H: Metabolic
dysfunction-associated steatohepatitis and progression to
hepatocellular carcinoma: A literature review. Cancers (Basel).
16:12142024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nassir F: NAFLD: Mechanisms, treatments,
and biomarkers. Biomolecules. 12:8242022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Akkız H, Gieseler RK and A Canbay A: Liver
fibrosis: From basic science towards clinical progress, focusing on
the central role of hepatic stellate cells. Int J Mol Sci.
25:78732024. View Article : Google Scholar
|
|
23
|
Malhi H and Gores GJ: Cellular and
molecular mechanisms of liver injury. Gastroenterology.
134:1641–1654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu X, Jiang J, Xu Q, Ni C, Yang L and
Huang D: A systematic review of long noncoding RNAs in
hepatocellular carcinoma: Molecular mechanism and clinical
implications. Biomed Res Int. 2018:81262082018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou L, Li M, Chai Z, Zhang J, Cao K, Deng
L, Liu Y, Jiao C, Zou GM, Wu J and Han F: Anticancer effects and
mechanisms of astragaloside-IV. Oncol Rep. 49:52022. View Article : Google Scholar
|
|
26
|
Yang Y, Hong M, Lian WW and Chen Z: Review
of the pharmacological effects of astragaloside IV and its
autophagic mechanism in association with inflammation. World J Clin
Cases. 10:10004–10016. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen C, Bu X, Deng L, Xia J, Wang X, Chen
L, Li W, Huang J, Chen Q and Wang C: Astragaloside IV as a
promising therapeutic agent for liver diseases: Current landscape
and future perspectives. Front Pharmacol. 16:15741542025.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang T, Chen X, Gao Q, Huang C, Wang K and
Qiu F: Herb-drug interaction potential of Astragali Radix: A
metabolic perspective. Drug Metab Rev. 57:9–25. 2025. View Article : Google Scholar
|
|
29
|
Zhang J, Wu C, Gao L, Du G and Qin X:
Astragaloside IV derived from Astragalus membranaceus: A research
review on the pharmacological effects. Adv Pharmacol. 87:89–112.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gu Y, Wang G, Pan G, Fawcett JP, J A and
Sun J: Transport and bioavailability studies of astragaloside IV,
an active ingredient in Radix Astragali. Basic Clin Pharmacol
Toxicol. 95:295–298. 2004. View Article : Google Scholar
|
|
31
|
Salehi B, Carneiro JNP, Rocha JE, Coutinho
HDM, Morais Braga MFB, Sharifi-Rad J, Semwal P, Painuli S, Moujir
LM, de Zarate Machado V, et al: Astragalus species: Insights on its
chemical composition toward pharmacological applications. Phytother
Res. 35:2445–2476. 2021. View Article : Google Scholar
|
|
32
|
Lu S, Chen KJ, Yang QY and Sun HR:
Progress in the research of Radix Astragali in treating chronic
heart failure: Effective ingredients, dose-effect relationship and
adverse reaction. Chin J Integr Med. 17:473–477. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fu S, Zhang J, Menniti-Ippolito F, Gao X,
Galeotti F, Massari M, Hu L, Zhang B, Ferrelli R, Fauci A, et al:
Huangqi injection (a traditional Chinese patent medicine) for
chronic heart failure: A systematic review. PLoS One. 6:e196042011.
View Article : Google Scholar :
|
|
34
|
Ziyang T, Xirong H, Chongming A and
Tingxin L: The potential molecular pathways of Astragaloside-IV in
colorectal cancer: A systematic review. Biomed Pharmacother.
167:1156252023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu Z, Zhou H, Zhang Y, Cheng Z, Wan M, Qin
W, Li P, Feng J, Shao S, Xue W, et al: Recent pharmacological
advances in the treatment of cardiovascular events with
Astragaloside IV. Biomed Pharmacother. 168:1157522023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yuan F, Yang Y, Liu L, Zhou P, Zhu Y, Chai
Y, Chen K, Tang W, Huang Q and Zhang C: Research progress on the
mechanism of astragaloside IV in the treatment of asthma. Heliyon.
9:e221492023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tan YQ, Chen HW and Li J: Astragaloside
IV: An effective drug for the treatment of cardiovascular diseases.
Drug Des Devel Ther. 14:3731–3746. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liang Y, Chen B, Liang D, Quan X, Gu R,
Meng Z, Gan H, Wu Z, Sun Y, Liu S and Dou G: pharmacological
effects of astragaloside IV: A review. Molecules. 28:61182023.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu Y, Zhou L, Yang Y and Liu Y:
Cycloastragenol: An exciting novel candidate for age-associated
diseases. Exp Ther Med. 16:2175–2182. 2018.PubMed/NCBI
|
|
40
|
Monschein M, Ardjomand-Woelkart K, Rieder
J, Wolf I, Heydel B, Kunert O, Heuberger H and Bauer R: Accelerated
sample preparation and formation of astragaloside IV in astragali
radix. Pharm Biol. Oct 30–2013.Epub ahead of print.
|
|
41
|
Chen Q, Su Y, Ju Y, Ma K and Li W and Li
W: Astragalosides IV protected the renal tubular epithelial cells
from free fatty acids-induced injury by reducing oxidative stress
and apoptosis. Biomed Pharmacother. 108:679–686. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Huang XP, Tan H, Chen BY and Deng CQ:
Astragalus extract alleviates nerve injury after cerebral ischemia
by improving energy metabolism and inhibiting apoptosis. Biol Pharm
Bull. 35:449–454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xia D, Li W, Tang C and Jiang J:
Astragaloside IV, as a potential anticancer agent. Front Pharmacol.
14:10655052023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhou R, Chen H, Chen J, Chen H, Wen Y and
Xu L: Extract from Astragalus membranaceus inhibit breast cancer
cells proliferation via PI3K/AKT/mTOR signaling pathway. BMC
Complement Altern Med. 18:832018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zang Y, Wan J, Zhang Z, Huang S, Liu X and
Zhang W: An updated role of astragaloside IV in heart failure.
Biomed Pharmacother. 126:1100122020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yao M, Zhang L and Wang L: Astragaloside
IV: A promising natural neuroprotective agent for neurological
disorders. Biomed Pharmacother. 159:1142292023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang WD, Zhang C, Liu RH, Li HL, Zhang
JT, Mao C, Moran S and Chen CL: Preclinical pharmacokinetics and
tissue distribution of a natural cardioprotective agent
astragaloside IV in rats and dogs. Life Sci. 79:808–815. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li L, Zhang Y, Luo Y, Meng X, Pan G, Zhang
H, Li Y and Zhang B: The molecular basis of the anti-inflammatory
property of astragaloside IV for the treatment of diabetes and its
complications. Drug Des Devel Ther. 17:771–790. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huang X, Zhou Y, Li Y, Wang T, Chen Y,
Zhou Y, Zhou X and Liu Q: Astragaloside IV inhibits inflammation
caused by influenza virus via reactive oxygen species/NOD-like
receptor thermal protein domain associated protein 3/Caspase-1
signaling pathway. Immun Inflamm Dis. 12:e13092024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang X, Zhang F, Li Y, Fan N, Zhao K,
Zhang A, Kang J, Lin Y, Xue X and Jiang X: Blockade of PI3K/AKT
signaling pathway by Astragaloside IV attenuates ulcerative colitis
via improving the intestinal epithelial barrier. J Transl Med.
22:4062024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sun Q, Hu M, Yuan C, Ren B, Zhong M, Zhou
S, Wang X, Gao Q, Zeng M, Cai X and Song H: Astragaloside IV
ameliorates indomethacin-induced intestinal inflammation in rats
through inhibiting the activation of NLRP3 inflammasome. Int
Immunopharmacol. 135:1122812024. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lu R, Chen J, Liu B, Lin H, Bai L, Zhang
P, Chen D, Li H, Li J, Pang Y, et al: Protective role of
Astragaloside IV in chronic glomerulonephritis by activating
autophagy through PI3K/AKT/AS160 pathway. Phytother Res.
34:3236–3248. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang X, Gao Y, Tian N, Zhu Z, Wang T, Xu
J, Wu B and Zhang N: Astragaloside IV represses high
glucose-induced mesangial cells activation by enhancing autophagy
via SIRT1 deacetylation of NF-κB p65 subunit. Drug Des Devel Ther.
12:2971–2980. 2018. View Article : Google Scholar
|
|
54
|
Wang Z, Wu Y, Pei C, Wang M, Wang X, Shi
S, Huang D, Wang Y, Li S, Xiao W, et al: Astragaloside IV
pre-treatment attenuates PM2.5-induced lung injury in rats: Impact
on autophagy, apoptosis and inflammation. Phytomedicine.
96:1539122022. View Article : Google Scholar
|
|
55
|
Yang B, Yang N, Chen Y, Zhu M, Lian Y,
Xiong Z, Wang B, Feng L and Jia X: An integrated strategy for
effective-component discovery of astragali radix in the treatment
of lung cancer. Front Pharmacol. 11:5809782021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Guo X, Yin X, Liu Z and Wang J:
Non-Alcoholic fatty liver disease (NAFLD) pathogenesis and natural
products for prevention and treatment. Int J Mol Sci. 23:154892022.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Grgurevic I, Podrug K, Mikolasevic I,
Kukla M, Madir A and Tsochatzis EA: Natural history of nonalcoholic
fatty liver disease: Implications for clinical practice and an
individualized approach. Can J Gastroenterol Hepatol.
2020:91813682020. View Article : Google Scholar :
|
|
58
|
Buzzetti E, Pinzani M and Tsochatzis EA:
The multiple-hit pathogenesis of non-alcoholic fatty liver disease
(NAFLD). Metabolism. 65:1038–1048. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wardani HA, Rahmadi M, Ardianto C, Balan
SS, Kamaruddin NS and Khotib J: Development of nonalcoholic fatty
liver disease model by high-fat diet in rats. J Basic Clin Physiol
Pharmacol.
30:/j/jbcpp.2019.30.issue-6/jbcpp-2019-0258/jbcpp-2019-0258.xml.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Puri P, Wiest MM, Cheung O, Mirshahi F,
Sargeant C, Min HK, Contos MJ, Sterling RK, Fuchs M, Zhou H, et al:
The plasma lipidomic signature of nonalcoholic steatohepatitis.
Hepatology. 50:1827–1838. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhai Y, Zhou W, Yan X, Qiao Y, Guan L,
Zhang Z, Liu H, Jiang J, Liu J and Peng L: Astragaloside IV
ameliorates diet-induced hepatic steatosis in obese mice by
inhibiting intestinal FXR via intestinal flora remodeling.
Phytomedicine. 107:1544442022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen CL and Lin YC: Autophagy
dysregulation in metabolic associated fatty liver disease: A new
therapeutic target. Int J Mol Sci. 23:100552022. View Article : Google Scholar :
|
|
63
|
Liu G, Wang YH, Zhang T, Li YQ, Chen XY,
Dong W, Li W, Miao QX, Qiao WB, Tian HQ and Yin SL:
Astragaloside-IV promotes autophagy via the Akt/mTOR pathway to
improve cellular lipid deposition. Medicine (Baltimore).
103:e378462024. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Liang XY, Hong FF and Yang SL:
Astragaloside IV alleviates liver inflammation, oxidative stress
and apoptosis to protect against experimental non-alcoholic fatty
liver disease. Diabetes Metab Syndr Obes. 14:1871–1883. 2021.
View Article : Google Scholar :
|
|
65
|
Snyder GA and Sundberg EJ: Molecular
interactions in interleukin and toll-like receptor signaling
pathways. Curr Pharm Des. 20:1244–1258. 2014. View Article : Google Scholar
|
|
66
|
Erridge C: Endogenous ligands of TLR2 and
TLR4: Agonists or assistants? J Leukoc Biol. 87:989–999. 2010.
View Article : Google Scholar
|
|
67
|
Liu YL, Zhang QZ, Wang YR, Fu LN, Han JS,
Zhang J and Wang BM: Astragaloside IV improves high-fat
diet-induced hepatic steatosis in nonalcoholic fatty liver disease
rats by regulating inflammatory factors level via TLR4/NF-κB
signaling pathway. Front Pharmacol. 11:6050642021. View Article : Google Scholar
|
|
68
|
Zhou B, Zhou DL, Wei XH, Zhong RL, Xu J
and Sun L: Astragaloside IV attenuates free fatty acid-induced ER
stress and lipid accumulation in hepatocytes via AMPK activation.
Acta Pharmacol Sin. 38:998–1008. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Asadi A, Shadab Mehr N, Mohamadi MH,
Shokri F, Heidary M, Sadeghifard N and Khoshnood S: Obesity and
gut-microbiota-brain axis: A narrative review. J Clin Lab Anal.
36:e244202022. View Article : Google Scholar :
|
|
70
|
Zhang Y, Du M, Wang J and Liu P:
Astragaloside IV relieves atherosclerosis and hepatic steatosis via
MAPK/NF-κB signaling pathway in LDLR-/- Mice. Front Pharmacol.
13:8281612022. View Article : Google Scholar
|
|
71
|
Li Z, Zhu JF and Ouyang H: Progress on
traditional Chinese medicine in improving hepatic fibrosis through
inhibiting oxidative stress. World J Hepatol. 15:1091–1108. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Cheung F, Feng Y, Wang N, Yuen MF, Tong Y
and Wong VT: Effectiveness of Chinese herbal medicine in treating
liver fibrosis: A systematic review and meta-analysis of randomized
controlled trials. Chin Med. 7:52012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Bataller R and Brenner DA: Liver fibrosis.
J Clin Invest. 115:209–218. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Chen Z, Yao L, Liu Y, Pan Z, Peng S, Wan
G, Cheng J, Wang J and Cao W: Astragaloside IV regulates
NF-κB-mediated cellular senescence and apoptosis of hepatic
stellate cells to suppress PDGF-BB-induced activation. Exp Ther
Med. 18:3741–3750. 2019.PubMed/NCBI
|
|
75
|
Li X, Wang X, Han C, Wang X, Xing G, Zhou
L, Li G and Niu Y: Astragaloside IV suppresses collagen production
of activated hepatic stellate cells via oxidative stress-mediated
p38 MAPK pathway. Free Radic Biol Med. 60:168–176. 2013. View Article : Google Scholar
|
|
76
|
Liu H, Wei W, Sun WY and Li X: Protective
effects of astragaloside IV on porcine-serum-induced hepatic
fibrosis in rats and in vitro effects on hepatic stellate cells. J
Ethnopharmacol. 122:502–508. 2009. View Article : Google Scholar
|
|
77
|
Zhao XM, Zhang J, Liang YN and Niu YC:
Astragaloside IV synergizes with ferulic acid to alleviate hepatic
fibrosis in bile duct-ligated cirrhotic rats. Dig Dis Sci.
65:2925–2936. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Bansal MB and Chamroonkul N: Antifibrotics
in liver disease: Are we getting closer to clinical use? Hepatol
Int. 13:25–39. 2019. View Article : Google Scholar
|
|
79
|
Odagiri N, Matsubara T, Sato-Matsubara M,
Fujii H, Enomoto M and Kawada N: Anti-fibrotic treatments for
chronic liver diseases: The present and the future. Clin Mol
Hepatol. 27:413–424. 2021. View Article : Google Scholar :
|
|
80
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49.
2024.PubMed/NCBI
|
|
81
|
Baecker A, Liu X, La Vecchia C and Zhang
ZF: Worldwide incidence of hepatocellular carcinoma cases
attributable to major risk factors. Eur J Cancer Prev. 27:205–212.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zhang Y, Zhang C, Wu N, Feng Y, Wang J, Ma
L and Chen Y: The role of exosomes in liver cancer: Comprehensive
insights from biological function to therapeutic applications.
Front Immunol. 15:14730302024. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Kalantari L, Ghotbabadi ZR, Gholipour A,
Ehymayed HM, Najafiyan B, Amirlou P, Yasamineh S, Gholizadeh O and
Emtiazi N: A state-of-the-art review on the NRF2 in Hepatitis
virus-associated liver cancer. Cell Commun Signal. 21:3182023.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Pugliese N, Alfarone L, Arcari I,
Giugliano S, Parigi TL, Rescigno M, Lleo A and Aghemo A: Clinical
features and management issues of NAFLD-related HCC: What we know
so far. Expert Rev Gastroenterol Hepatol. 17:31–43. 2023.
View Article : Google Scholar
|
|
86
|
Jacob R, Prince DS, Kench C and Liu K:
Alcohol and its associated liver carcinogenesis. J Gastroenterol
Hepatol. 38:1211–1217. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Jin J, Kouznetsova VL, Kesari S and
Tsigelny IF: Synergism in actions of HBV with aflatoxin in cancer
development. Toxicology. 499:1536522023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Hamid AS, Tesfamariam IG, Zhang Y and
Zhang ZG: Aflatoxin B1-induced hepatocellular carcinoma in
developing countries: Geographical distribution, mechanism of
action and prevention. Oncol Lett. 5:1087–1092. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Pathomjaruwat T, Matchim Y and Armer JM:
Symptoms and symptom clusters in patients with hepatocellular
carcinoma and commonly used instruments: An integrated review. Int
J Nurs Sci. 11:66–75. 2023.
|
|
90
|
Xue Y, Ruan Y, Wang Y, Xiao P and Xu J:
Signaling pathways in liver cancer: Pathogenesis and targeted
therapy. Mol Biomed. 5:202024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Chan YT, Zhang C, Wu J, Lu P, Xu L, Yuan
H, Feng Y, Chen ZS and Wang N: Biomarkers for diagnosis and
therapeutic options in hepatocellular carcinoma. Mol Cancer.
23:1892024. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Mehta N, Dodge JL, Roberts JP and Yao FY:
Validation of the prognostic power of the RETREAT score for
hepatocellular carcinoma recurrence using the UNOS database. Am J
Transplant. 18:1206–1213. 2018. View Article : Google Scholar
|
|
93
|
Zhu Y and Lu F: Astragaloside IV inhibits
cell viability and glycolysis of hepatocellular carcinoma by
regulating KAT2A-mediated succinylation of PGAM1. BMC Cancer.
24:6822024. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Fang Gong Y, Hou S, Xu JC, Chen Y, Zhu LL,
Xu YY, Chen YQ, Li MM, Li LL, Yang JJ and Yang Y: Amelioratory
effects of astragaloside IV on hepatocarcinogenesis via
Nrf2-mediated pSmad3C/3L transformation. Phytomedicine.
117:1549032023. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Li L, Wang Q, He Y, Sun L, Yang Y and Pang
X: Astragaloside IV suppresses migration and invasion of
TGF-β1-induced human hepatoma HuH-7 cells by regulating Nrf2/HO-1
and TGF-β1/Smad3 pathways. Naunyn Schmiedebergs Arch Pharmacol.
395:397–405. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Min L, Wang H and Qi H: Astragaloside IV
inhibits the progression of liver cancer by modulating macrophage
polarization through the TLR4/NF-κB/STAT3 signaling pathway. Am J
Transl Res. 14:1551–1566. 2022.
|
|
97
|
Ma Y, Li Y, Wu T, Li Y and Wang Q:
Astragaloside IV attenuates programmed death-ligand 1-mediated
immunosuppression during liver cancer development via the
miR-135b-5p/CNDP1 Axis. Cancers (Basel). 15:50482023. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Cui X, Jiang X, Wei C, Xing Y and Tong G:
Astragaloside IV suppresses development of hepatocellular carcinoma
by regulating miR-150-5p/β-catenin axis. Environ Toxicol Pharmacol.
78:1033972020. View Article : Google Scholar
|
|
99
|
Guo H, Zhao J and Wu C: Astragaloside
IV-enhanced anti-hepatocarcinoma immunity of dendritic cells. Asian
J Surg. 45:1216–1218. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Qi H, Wei L, Han Y, Zhang Q, Lau AS and
Rong J: Proteomic characterization of the cellular response to
chemopreventive triterpenoid astragaloside IV in human
hepatocellular carcinoma cell line HepG2. Int J Oncol. 36:725–735.
2010.PubMed/NCBI
|
|
101
|
Wang PP, Xu DJ, Huang C, Wang WP and Xu
WK: Astragaloside Ⅳ reduces the expression level of P-glycoprotein
in multidrug-resistant human hepatic cancer cell lines. Mol Med
Rep. 9:2131–2137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Qu X, Gao H, Zhai J, Sun J, Tao L, Zhang
Y, Song Y and Hu T: Astragaloside IV enhances cisplatin
chemosensitivity in hepatocellular carcinoma by suppressing MRP2.
Eur J Pharm Sci. 148:1053252020. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Su CM, Wang HC, Hsu FT, Lu CH, Lai CK,
Chung JG and Kuo YC: Astragaloside IV induces apoptosis, G1-Phase
arrest and inhibits anti-apoptotic signaling in hepatocellular
carcinoma. In Vivo. 34:631–638. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Qin CD, Ma DN, Ren ZG, Zhu XD, Wang CH,
Wang YC, Ye BG, Cao MQ, Gao DM and Tang ZY: Astragaloside IV
inhibits metastasis in hepatoma cells through the suppression of
epithelial-mesenchymal transition via the Akt/GSK-3β/β-catenin
pathway. Oncol Rep. 37:1725–1735. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Jiang Z and Mao Z: Astragaloside IV
(AS-IV) alleviates the malignant biological behavior of
hepatocellular carcinoma via Wnt/beta-catenin signaling pathway.
RSC Adv. 9:35473–35482. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Dai S, Fu K, Liu Y, Yao Y, Zhang F, Wu R,
Guo Y, Yao C and Li Y: Vitexin: A dietary flavonoid with potential
protective effects against liver diseases. Food Rev Int.
40:3254–3290. 2024. View Article : Google Scholar
|
|
107
|
Ko S, Russell JO, Molina LM and Monga SP:
Liver progenitors and adult cell plasticity in hepatic injury and
repair: Knowns and unknowns. Annu Rev Pathol. 15:23–50. 2020.
View Article : Google Scholar
|
|
108
|
Hu PF and Xie WF: Corticosteroid therapy
in drug-induced liver injury: Pros and cons. J Dig Dis. 20:122–126.
2019. View Article : Google Scholar
|
|
109
|
Stravitz RT and Lee WM: Acute liver
failure. Lancet. 394:869–881. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Dossi CG, Vargas RG, Valenzuela R and
Videla LA: Beneficial effects of natural compounds on experimental
liver ischemia-reperfusion injury. Food Funct. 12:3787–3798. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Rani J, Dhull SB, Rose PK and Kidwai MK:
Drug-induced liver injury and anti-hepatotoxic effect of herbal
compounds: A metabolic mechanism perspective. Phytomedicine.
122:1551422024. View Article : Google Scholar
|
|
112
|
Cengiz M, Cetik Yildiz S, Demir C, Şahin
IK, Teksoy O and Ayhanci A: Hepato-preventive and anti-apoptotic
role of boric acid against liver injury induced by
cyclophosphamide. J Trace Elem Med Biol. 53:1–7. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Liu C, Wang R, Zhang B, Hu C and Zhang H:
Protective effects of lycopene on oxidative stress, proliferation
and autophagy in iron supplementation rats. Biol Res. 46:189–200.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Ramm GA and Ruddell RG: Hepatotoxicity of
iron overload: Mechanisms of iron-induced hepatic fibrogenesis.
Semin Liver Dis. 25:433–449. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Corradini E, Ferrara F and Pietrangelo A:
Iron and the liver. Pediatr Endocrinol Rev. 2(Suppl 2) (2004):
S245–S248. 2004.
|
|
116
|
Xie D, Zhou P, Liu L, Jiang W, Xie H,
Zhang L and Xie D: Protective effect of astragaloside IV on hepatic
injury induced by iron overload. Biomed Res Int. 2019:31039462019.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Gao Y, Chu S, Shao Q, Zhang M, Xia C, Wang
Y, Li Y, Lou Y, Huang H and Chen N: Antioxidant activities of
ginsenoside Rg1 against cisplatin-induced hepatic injury through
Nrf2 signaling pathway in mice. Free Radic Res. 51:1–13. 2017.
View Article : Google Scholar
|
|
118
|
Romani AMP: Cisplatin in cancer treatment.
Biochem Pharmacol. 206:1153232022. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Pezeshki Z, Khosravi A, Nekuei M,
Khoshnood S, Zandi E, Eslamian M, Talebi A, Emami SN and
Nematbakhsh M: Time course of cisplatin-induced nephrotoxicity and
hepatotoxicity. J Nephropathol. 6:163–167. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Tarladacalisir YT, Uygun M, Akpolat M and
UZ YH: Histologic examination of the protective effect of vitamin E
and C in cisplatin-induced hepatotoxicity. Trakya Univ Tip Fak
Derg. 22:124–131. 2005.
|
|
121
|
Qu X, Gao H, Tao L, Zhang Y, Zhai J, Sun
J, Song Y and Zhang S: Astragaloside IV protects against
cisplatin-induced liver and kidney injury via autophagy-mediated
inhibition of NLRP3 in rats. J Toxicol Sci. 44:167–175. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Guo J, Le Y, Yuan A, Liu J, Chen H, Qiu J,
Wang C, Dou X, Yuan X and Lu D: Astragaloside IV ameliorates
cisplatin-induced liver injury by modulating ferroptosis-dependent
pathways. J Ethnopharmacol. 328:1180802024. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Chen J, Li X, Ge C, Min J and Wang F: The
multifaceted role of ferroptosis in liver disease. Cell Death
Differ. 29:467–480. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Guo J, Yin J, Liu P, Zhang X, Wei J, Wang
M, Xiao Y, Zhen Y, Lin Y and Li J: Glycyrrhizin arginine salt
protects against cisplation-induced acute liver injury by
repressing BECN1-mediated ferroptosis. Front Pharmacol.
14:12194862023. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Saito C, Zwingmann C and Jaeschke H: Novel
mechanisms of protection against acetaminophen hepatotoxicity in
mice by glutathione and N-acetylcysteine. Hepatology. 51:246–254.
2010. View Article : Google Scholar
|
|
127
|
Kim SJ, Kim KM, Yang JH, Cho SS, Kim JY,
Park SJ, Lee SK, Ku SK, Cho IJ and Ki SH: Sestrin2 protects against
acetaminophen-induced liver injury. Chem Biol Interact. 269:50–58.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Bunchorntavakul C and Reddy KR:
Acetaminophen (APAP or N-Acetyl-p-Aminophenol) and acute liver
failure. Clin Liver Dis. 22:325–346. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Li L, Huang W, Wang S, Sun K, Zhang W,
Ding Y, Zhang L, Tumen B, Ji L and Liu C: Astragaloside IV
attenuates acetaminophen-induced liver injuries in mice by
activating the Nrf2 signaling pathway. Molecules. 23:20322018.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Perez-Calahorra S, Laclaustra M,
Marco-Benedi V, Pinto X, Sanchez-Hernandez RM, Plana N, Ortega E,
Fuentes F and Civeira F: Comparative efficacy between atorvastatin
and rosuvastatin in the prevention of cardiovascular disease
recurrence. Lipids Health Dis. 18:2162019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Qin L, Wang Y, Liang Y, Li Q, Xie X and
Zhang H: Astragaloside IV alleviates atorvastatin-induced
hepatotoxicity via AMPK/SIRT1 pathway. Pharmacology. 108:74–82.
2023. View Article : Google Scholar
|
|
132
|
Osna NA, Donohue TM Jr and Kharbanda KK:
Alcoholic liver disease: Pathogenesis and current management.
Alcohol Res. 38:147–161. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Wu S, Wen F, Zhong X, Du W, Chen M and
Wang J: Astragaloside IV ameliorate acute alcohol-induced liver
injury in mice via modulating gut microbiota and regulating
NLRP3/caspase-1 signaling pathway. Ann Med. 55:22169422023.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Wu D and Cederbaum AI: Oxidative stress
and alcoholic liver disease. Semin Liver Dis. 29:141–154. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Han L, Li J, Lin X, Ma YF and Huang YF:
(Protective effect of astragaloside IV on oxidative damages of
chang liver cell induced by ethanol and H2O2). Zhongguo Zhong Yao
Za Zhi. 39:4430–4435. 2014.In Chinese.
|
|
136
|
Albillos A, de Gottardi A and Rescigno M:
The gut-liver axis in liver disease: Pathophysiological basis for
therapy. J Hepatol. 72:558–577. 2020. View Article : Google Scholar
|
|
137
|
Hao J, Hu R, Zhao J, Li Y, Li Q and Zhang
X: Metabolomics combined with network pharmacology reveals the
protective effect of astragaloside IV on alcoholic liver disease.
Phytomedicine. 135:1560322024. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Ingawale DK, Mandlik SK and Naik SR:
Models of hepatotoxicity and the underlying cellular, biochemical
and immunological mechanism(s): A critical discussion. Environ
Toxicol Pharmacol. 37:118–133. 2014. View Article : Google Scholar
|
|
139
|
Zhang G, Li J, Xu Z, Zhou K, Zhao X, Wu X,
Liang C, Lai Z, Cheng Y, Meng C, Huang J and Deng Z: Exocarpium
citri grandis attenuates lipopolysaccharide-induced acute liver
injury through suppression of inflammatory, apoptotic, oxidative,
and ferroptotic pathways. Food Sci Nutr. 13:e710122025. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Sun Y, Ma Y, Sun F, Feng W, Ye H, Tian T
and Lei M: Astragaloside IV attenuates lipopolysaccharide induced
liver injury by modulating Nrf2-mediated oxidative stress and
NLRP3-mediated inflammation. Heliyon. 9:e154362023. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Shima T, Uto H, Ueki K, Takamura T, Kohgo
Y, Kawata S, Yasui K, Park H, Nakamura N, Nakatou T, et al:
Clinicopathological features of liver injury in patients with type
2 diabetes mellitus and comparative study of histologically proven
nonalcoholic fatty liver diseases with or without type 2 diabetes
mellitus. J Gastroenterol. 48:515–525. 2013. View Article : Google Scholar
|
|
142
|
Tan SY, Mei Wong JL, Sim YJ, Wong SS,
Mohamed Elhassan SA, Tan SH, Ling Lim GP, Rong Tay NW, Annan NC,
Bhattamisra SK and Candasamy M: Type 1 and 2 diabetes mellitus: A
review on current treatment approach and gene therapy as potential
intervention. Diabetes Metab Syndr. 13:364–372. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Kumar V, Xin X, Ma J, Tan C, Osna N and
Mahato RI: Therapeutic targets, novel drugs, and delivery systems
for diabetes associated NAFLD and liver fibrosis. Adv Drug Deliv
Rev. 176:1138882021. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Targher G, Corey KE, Byrne CD and Roden M:
The complex link between NAFLD and type 2 diabetes
mellitus-mechanisms and treatments. Nat Rev Gastroenterol Hepatol.
18:599–612. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Stefan N and Cusi K: A global view of the
interplay between non-alcoholic fatty liver disease and diabetes.
Lancet Diabetes Endocrinol. 10:284–296. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Zhu Y, Su Y, Zhang J, Zhang Y, Li Y, Han
Y, Dong X and Li W and Li W: Astragaloside IV alleviates liver
injury in type 2 diabetes due to promotion of AMPK/mTOR-mediated
autophagy. Mol Med Rep. 23:4372021. View Article : Google Scholar
|
|
147
|
Liu J and Man K: Mechanistic insight and
clinical implications of ischemia/reperfusion injury post liver
transplantation. Cell Mol Gastroenterol Hepatol. 15:1463–1474.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Cheng MX, Chen ZZ, Cai YL, Liu CA and Tu
B: Astragaloside IV protects against ischemia reperfusion in a
murine model of orthotopic liver transplantation. Transplant Proc.
43:1456–1461. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Zhang Q, Zhu LL, Chen GG and Du Y:
Pharmacokinetics of astragaloside iv in beagle dogs. Eur J Drug
Metab Pharmacokinet. 32:75–79. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Chang YX, Sun YG, Li J, Zhang QH, Guo XR,
Zhang BL, Jin H and Gao XM: The experimental study of Astragalus
membranaceus on meridian tropsim: The distribution study of
astragaloside IV in rat tissues. J Chromatogr B Analyt Technol
Biomed Life Sci. 911:71–75. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Xu M, Yin J, Xie L, Zhang J, Zou C, Zou J,
Liu F, Ju W and Li P: Pharmacokinetics and tolerance of toal
astragalosides after intravenous infusion of astragalosides
injection in healthy Chinese volunteers. Phytomedicine.
20:1105–1111. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Du Y, Zhang Q, Chen GG, Wei P and Tu CY:
Pharmacokinetics of Astragaloside IV in rats by liquid
chromatography coupled with tandem mass spectrometry. Eur J Drug
Metab Pharmacokinet. 30:269–273. 2005. View Article : Google Scholar
|
|
153
|
Gui D, Guo Y, Wang F, Liu W, Chen J, Chen
Y, Huang J and Wang N: Astragaloside IV, a novel antioxidant,
prevents glucose-induced podocyte apoptosis in vitro and in vivo.
PLoS One. 7:e398242012. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Yu SY, Ouyang HT, Yang JY, Huang XL, Yang
T, Duan JP, Cheng JP, Chen YX, Yang YJ and Qiong P: Subchronic
toxicity studies of Radix Astragali extract in rats and dogs. J
Ethnopharmacol. 110:352–355. 2007. View Article : Google Scholar
|
|
155
|
Jiangbo Z, Xuying W, Yuping Z, Xili M,
Yiwen Z and Tianbao Z: Effect of astragaloside IV on the
embryo-fetal development of Sprague-Dawley rats and New Zealand
White rabbits. J Appl Toxicol. 29:381–385. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Xuying W, Jiangbo Z, Yuping Z, Xili M,
Yiwen Z, Tianbao Z and Weidong Z: Effect of astragaloside IV on the
general and peripartum reproductive toxicity in Sprague-Dawley
rats. Int J Toxicol. 29:505–516. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Singh R and Lillard JW Jr:
Nanoparticle-based targeted drug delivery. Exp Mol Pathol.
86:215–223. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Zhao X, Sun L, Wang J, Xu X, Ni S, Liu M
and Hu K: Nose to brain delivery of Astragaloside IV by β-Asarone
modified chitosan nanoparticles for multiple sclerosis therapy. Int
J Pharm. 644:1233512023. View Article : Google Scholar
|
|
159
|
Yue Y, Liu X, Pang L, Liu Y, Lin Y, Xiang
T, Li J, Liao S and Jiang Y: Astragalus polysaccharides/PVA
nanofiber membranes containing astragaloside IV-Loaded liposomes
and their potential use for wound healing. Evid Based Complement
Alternat Med. 2022:97162712022. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Kong C, Sun J, Hu X, Li G and Wu S: A
tumor targeted nano micelle carrying astragaloside IV for
combination treatment of bladder cancer. Sci Rep. 14:177042024.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Sun R, Zhang A, Ge Y, Gou J, Yin T, He H,
Wang Y, Zhang G, Kong J, Shang L, et al: Ultra-small-size
Astragaloside-IV loaded lipid nanocapsules eye drops for the
effective management of dry age-related macular degeneration.
Expert Opin Drug Deliv. 17:1305–1320. 2020. View Article : Google Scholar : PubMed/NCBI
|
